Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACS: Anticoagulation vs Antiplatelet Therapy for Secondary Prevention in Ischemic Stroke
NCT07746882Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2026
- Primary completion
- Aug 2028
01
Overview
Phase 3, randomised trial of rivaroxaban, edoxaban, apixaban and dabigatran etexilate oral solution in ischemic stroke (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Ischemic stroke recurrence at 3 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
rivaroxabanedoxabanapixabandabigatran etexilate oral solution
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07746882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746882.